Αρχική World News Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is Generally...

Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is Generally Well-Tolerated

Dr. Brian D. Gonzalez of Moffitt Cancer Center in Tampa, USA presented findings from two meta-analyses at ESMO Virtual Congress 2020 which were designed to summarise quality of life (QoL) data to better educate patients receiving immune checkpoint inhibitor (ICI) therapy for cancer. These meta-analyses found that patients receiving ICI had better QoL than patients receiving non-ICI treatment.

Dr Gonzalez reported findings on behalf of colleagues from this study, which was conducted with the aim of summarising QoL data to make QoL information more accessible to patients receiving ICI for cancer.

Patients treated with ICIs reported less change in QoL

The two meta-analyses were performed on publications of PD-1/PD-L1 and/or CTLA-4 inhibitors that provided mean-level QoL using the EORTC QLQ-C30 and/or EQ-5D questionnaires. One meta-analysis examined change in QoL in patients treated with ICIs from pre-treatment to follow-up, which occurred approximately 12 to 24 weeks later. The second meta-analysis compared QoL at follow-up between ICI and non-ICI regimens in randomised trials. Both had moderator analyses examining ICI regimen, comparator regimen, disease site, age, gender, follow-up period and risk of bias.

The investigators identified 20,323 publications, of which 26 studies met the inclusion criteria.

The first meta-analysis, which comprised 26 studies and 6,965 patients, indicated that QoL did not change over time in patients following ICI treatment (p > 0.05). Some subgroups reported improvements in QoL, such as patients treated with certain ICIs or for certain cancer types. Other significant moderators included sex and risk of bias (p values < 0.05).

Quantitative-Summary-of-QoL-Data-Confirms-Immune-Checkpoint-Inhibitor-Therapy-Is-Generally-Well-Tolerated-1568O

Overall, quality of life did not change after ICI treatment, but changes were evident in some subgroups.

© Brian D. Gonzalez.

The second meta-analysis consisted of 16 studies and 6,536 patients; among these patients, 3,588 received ICI treatment and 2,948 patients received other, non-ICI therapy.  Better follow-up QoL was observed in patients receiving ICI versus non-ICI regimens (p < 0.05). Significant moderators in this analysis included ICI regimen, cancer type, age and risk of bias (p values < 0.05).

Conclusions

The authors noted that their study is among the first to quantitatively summarise QoL in patients treated with ICIs.

These findings suggest that patients treated with ICIs have more stable and better QoL overall than patients treated with non-ICI regimens for similar cancer.

They concluded that these results confirm that, despite immune-related toxicities, ICIs are generally well-tolerated.

Funding for this study was reported from the US National Cancer Institute (grant K01 CA211789).

Reference

1568O – Gonzalez BD, Eisel SL, Bowles KE, et al. Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. ESMO Virtual Congress 2020.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

De qué manera el seguimiento de los síntomas mejora la atención oncológica

Se sabe bien que el tratamiento contra el cáncer genera efectos secundarios significativos. Por ejemplo, la quimioterapia puede causar caída del cabello, náuseas e...

Man Who Lost His Mother to Breast Cancer Opens Resource Center in Her Memory

After the death of a beloved parent, you can find yourself wanting to carry their legacy forward in their absence. One man in Ohio...

Navigating Cancer Survivorship as a Transgender or Non-Binary Person

Mal Malme (Mal or they/them) is a proud Boston-based theater artist, activist, writer, and health care clown. Mal is co-founder of Queer Soup Theater...

Sing Anyway

“Some days there won’t be a song in your heart. Sing anyway.” – Emory Austin I love this thought from Emory Austin. I am reminded...

Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer

May 5, 2021, by NCI Staff A small clinical trial tested the combination of topotecan with the drug berzosertib, which inhibits a protein that helps repair...

Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical Cancer

A group of US investigators found a substantial decrease in the use of minimally invasive surgery, robotic or laparoscopic, for cervical cancer after publication...